Serum Fucose Level is a Reliable Biomarker to Astrocytoma: Case-control study-A systematic study and meta-analysis

Abstract

Cancer is one of the main leading diseases causing death. The current study aims to evaluate the concentration of fucose in the blood serum of astrocytoma patients. Also, a systematic study with sequential meta-analysis was performed. Web of Science, PubMed, EBSCO and Scopus, and published reference lists were searched up to end of May 2023. This meta-analysis indicates a statistically significant mean difference in fucose in serum between cancer patients and controls . The current search included 12 of 3611 titles: 562 cancer cases and 401 normal. Meta-analysis concluded that serum fucose can differentiate cancer patients from controls. Significant heterogeneity was found between studies: P < 0.0001 and I2 94.48%. A significant publication bias was observed (Begg, p = 0007; E gger, p = 0. 00092). there was a differences in Forest Plot of TF level between patients and control groups. Also, study estimated pooled effect size